How Far Do Prices Fall When a Drug Goes Generic?

Today the most useful fact about generic drug prices is a pair of numbers from the Food and Drug Administration, and the pair tells you more than either number alone. FDA data, as summarized by DrugPatentWatch, show generics at “approximately 39% below the brand price when there is one generic producer, and more than 95% below the brand price when there are six or more generic producers.” So the honest answer to the title question is that it depends almost entirely on how many companies show up.

That is the plain version. The rest of the evidence fills in timing and product type. A systematic literature review found prices 34% to 93.4% lower in the one to five years after patent expiry, with a lot of variation by country and drug class. Injectable peptides have also tended to fall much less than pills. GLP-1 drugs are injectable peptides whose patents are now expiring around the world, so all three variables apply to them at once.

Why the first generic is only a little cheaper

Follow the money one link at a time. The brand company gets paid for having a monopoly, and in the US the Hatch-Waxman Act of 1984 helps it keep one: listing patents in the FDA’s Orange Book can trigger an automatic 30-month stay of a generic’s approval. When the first generic finally arrives, it is not competing with forty rivals. It is competing with the brand, which charges a lot.

So what should the first generic charge? It only needs to be cheaper than the brand, and the brand is very expensive. Basically the first generic is playing The Price Is Right in reverse: the winning bid is the one closest to the brand’s price while still being clearly under it. (I assume nobody describes it that way in an actual pricing meeting.)

Here is an invented version of that meeting, clearly made up: “Hey guys, we’re the only generic, the pharmacies will take us at 39% off, why would we offer them 95%?” It is a perfectly reasonable thing to say. It also stops being true the moment a second company gets approved.

The arrangement looks a lot like two gas stations at the same intersection, which tend to price within a few cents of each other because each one’s real competitor is the sign across the street. It is the third and fourth stations that start the price war. Six stations is a commodity.

Other countries build the value of the first slot into law. China’s 2021 patent linkage rules give 12 months of market exclusivity to the first small-molecule generic applicant that invalidates a listed patent and wins approval, and the outlet VCBeat writes that “first generic” status in China “establishes a unique competitive position that is difficult for competitors to shake.” The prize for coming first is being the only generic for a while, which is to say the prize is not having to cut prices very much. The incentive points the wrong way.

How long generic drug prices take to fall

The review’s range is wide because time is doing most of the work. I feel like the timing question is really a headcount question: how fast do generics two through six arrive?

The US liraglutide story is the slow version. Teva launched the first-ever US generic GLP-1, an authorized generic of Victoza, on June 24, 2024, under a 2019 patent settlement with Novo Nordisk. (An authorized generic is the brand and a generic maker getting into bed together on the terms of the brand’s own competition, which is less exciting than it sounds.) At launch it cost $469.60 for a two-pack against about $560 for the brand, a 16% to 17% discount. Not 95%.

More competition from Sandoz and Viatris was expected from December 2024 onward, and by 2026 GoodRx’s average price range for Teva’s generic two-pen package was $200 to $450. At the low end that is less than half the launch price. At the high end it is roughly the launch price, which is the sort of thing an average range will do to a tidy story.

India is the fast version. Over 40 generic semaglutide brands launched on March 21, 2026, the day after the patent expired. Ozempic had cost 8,800 to 11,175 rupees a month (roughly $100 to $130), and the generics came in at 1,800 to 4,200 rupees (roughly $20 to $50). By October 8, 2026, the lowest stated monthly price was 1,290 rupees (roughly $15), for vials from Natco and Eris.

Forty entrants on day one. That skips the gas stations.

Then the chain grows a link nobody expects. About ten days after the launches, Novo Nordisk cut its Indian price for Ozempic by 36% and for Wegovy by 48%. The brand, whose whole business model was not competing on price, started competing on price, which is the generics doing their job twice: once with their own product and once with the brand’s.

Injectables are not pills, except sometimes legally

The second variable is what kind of drug it is. According to Prost Biotech, US peptide generic and biosimilar drugs “typically achieve only 15-40% price reductions versus reference products,” compared to 80% to 90% for small-molecule generics, because the biosimilar approval pathway is more expensive. An expensive pathway means fewer companies try. Fewer companies keep you near the 39% end of the FDA curve.

So semaglutide, a peptide, should go through the expensive pathway and fall modestly. Actually, no. The FDA treats peptide chains under 40 amino acids as generic drugs, which puts semaglutide (31 amino acids) and tirzepatide (39) on the generic side of the line, and Apotex received the first US tentative approval for a generic semaglutide injection, through an Abbreviated New Drug Application, announced April 10, 2026. So semaglutide is a peptide that is legally a generic, and whether its US price behaves like a pill’s or like a biologic’s is not settled, because nothing has launched yet to measure. (Tirzepatide clears the line by a single amino acid, which is a very specific thing to have a drug’s pricing depend on.)

Pills, on the other hand, have their own surprise. In India a formulation patent on the SNAC absorption enhancer used in oral semaglutide runs to 2031, blocking generic Rybelsus-type tablets even though the injection is open. Usually the pill is the cheap generic. Here it stays patented.

What happens when a country writes the rule down

Brazil skips the waiting: generics must by law be sold at least 35% below the reference product’s price, and with several makers the discounts typically reach 50% to 80%. That floor sits close to the FDA’s one-generic number, which I suppose is what a legislature looks like when it writes down the price a lone first generic would have charged anyway and lets the market handle the rest. (I read price-ratio tables for fun, so my sense of what counts as elegant is suspect.)

China had 12 semaglutide generics from 10 companies filed with its regulator by March 20, 2026, some as modified new drugs and some as generic biologics, two routes for one molecule. Canada approved versions from Dr. Reddy’s and Apotex, and a write-up in Legal 500 describes it as a potential “guinea pig” for generic semaglutide pricing, with implications for US importation. To be fair, the US has its own parallel track: semaglutide is in Medicare’s second round of price negotiation, so it may end up with a negotiated price and a generic price, set by two unrelated mechanisms, at about the same time.

The best-studied rule in generic pricing is that the brand’s price falls with each new competitor, and the cleanest test of it this year needed no regulator at all. The most effective drug price regulator in India in 2026 was a calendar, and it only had to work for one day.